Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 2;3(2):00081-2016.
doi: 10.1183/23120541.00081-2016. eCollection 2017 Apr.

Pembrolizumab-induced pneumonitis

Vincent Leroy  1 , Carole Templier  2 , Jean-Baptiste Faivre  3 , Arnaud Scherpereel  4   5 , Clement Fournier  6 , Laurent Mortier  2   7 , Lidwine Wemeau-Stervinou  1
Affiliations

Pembrolizumab-induced pneumonitis

Vincent Leroy et al. ERJ Open Res. .

Abstract

Three cases of pembrolizumab-induced pneumonitis are described, two being consistent with organising pneumonia http://ow.ly/Dvhc308QI39.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at openres.ersjournals.com

Figures

FIGURE 1
FIGURE 1
a) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1, after empiric antibiotics; d) CT scan of patient number 1, 3 months after corticosteroids were started; e) CT scan of patient number 2 before pembrolizumab; f) CT scan of patient number 2, after 4 pembrolizumab infusions; g) CT scan of patient number 2,1 month after pembrolizumab was stopped; h) CT scan of patient number 2, 2 months after corticosteroids were started; i) CT scan of patient number 3, before pembrolizumab; j) CT scan of patient number 3, after 4 pembrolizumab infusions; k) CT scan of patient number 3, 2 months after pembrolizumab was stopped.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tumeh PC, Harview CL, Yearley JH, et al. . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568–571. - PMC - PubMed
    1. Garon EB, Rizvi NA, Hui R, et al. . Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 2015; 372: 2018–2028. - PubMed
    1. Robert C, Schachter J, Long GV, et al. . Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–2532. - PubMed
    1. Ribas A, Puzanov I, Dummer R, et al. . Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908–918. - PMC - PubMed
    1. Borghaei H, Paz-Ares L, Horn L, et al. . Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627–1639. - PMC - PubMed

LinkOut - more resources